eISSN: 2391-6052
ISSN: 2353-3854
Alergologia Polska - Polish Journal of Allergology
Current issue Archive Manuscripts accepted About the journal Supplements Special issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
4/2022
vol. 9
 
Share:
Share:
abstract:
Original paper

The safety of celecoxib in cutaneous hypersensitivity reactions with nonsteroidal anti-inflammatory drugs: a single-center care experience

Mehmet Erdem Cakmak
1

  1. Department of Allergy and Clinical Immunology, Başakşehir Çam and Sakura City Hospital, Istanbul, Turkey
Alergologia Polska – Polish Journal of Allergology 2022; 9, 4: 250–255
Online publish date: 2022/12/09
View full text Get citation
 
PlumX metrics:
Introduction
Aspirin/non-steroidal anti-inflammatory drugs (NSAIDs) are frequently prescribed, and hypersensitivity reactions to these drugs are frequently observed in clinical practice.

Aim
To evaluate the safety of celecoxib in patients with a history of cutaneous hypersensitivity reactions to NSAIDs.

Material and methods
A retrospective evaluation was made of a total of 113 patients with a history of cutaneous hypersensitivity reactions to NSAIDs who underwent a drug challenge test with celecoxib. The diagnosis of NSAID hypersensitivity was based on a positive oral aspirin challenge test result or a recorded and significant clinical hypersensitivity reaction to aspirin and/or other NSAID-induced reaction.

Results
A total of 113 patients (40 (35.4%) male, 73 (64.6%) female) with a mean age of 39.64 ±12.65 years underwent the drug challenge with celecoxib. Atopy was determined in 40 (35.4%) patients. The most common accompanying allergic diseases were asthma in 46 (40.7%) patients and allergic rhinitis in 37 (32.7%) patients. The most common NSAIDs responsible for the allergic reaction were diclofenac (48.7%), flurbiprofen (47.8%), ketoprofen (47.8%), and aspirin (45.1%). No allergic reaction to celecoxib was observed in any of the 113 patients who underwent the drug challenge testing.

Conclusions
Celecoxib is a safe alternative drug in patients with a history of cutaneous hypersensitivity reactions to NSAIDs.

keywords:

aspirin, celecoxib, drug allergy, drug hypersensitivity, non-steroidal anti-inflammatory agents



Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.